African horse-sickness killed-virus tissue culture vaccine.

This research article presents findings on the effectiveness of an inactivated African horse-sickness (AHS) type 9 virus vaccine, grown in monkey kidney cell cultures, in immunizing and protecting horses from infection.

Experiment Setup

• The researchers used a formalized African horse-sickness (AHS) type 9 virus, cultivated in monkey kidney stable (MS) cell cultures, to immunize horses. This use of formalin-inactivated viruses, common in vaccine manufacture, aims to trigger the immune response without causing the disease.

Type of Vaccines Tested

• The researchers prepared and tested inactivated vaccines from either the viscerotropic or neurotropic types of the AHS virus. In general, viscerotropic viruses affect the internal organs, while neurotropic viruses primarily attack the nervous system.

Vaccine Efficiency

• The researchers found that the tested vaccines produced antibodies in the vaccinated horses. Antibodies are vital components of a horse’s immune defense, binding to foreign organisms and neutralizing them or marking them for destruction by the immune system.

Protection Against Infection

• After vaccination, all the horses developed immunity and were subsequently protected from infection. This suggests that the vaccine was effective in training the horses’ immune systems to recognize and protect against the AHS virus.

Challenge Test Post-Vaccination

• The researchers administered a challenge test five weeks after vaccination. This type of test involves exposing the vaccinated subjects to the pathogen in order to determine the effectiveness and longevity of the vaccine-induced immunity. The horses’ continued protection indicates a strong, lasting immunity induced by the vaccine.